Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. […]
AOBiome Therapeutics (“AOBiome”), a clinical-stage life sciences company advancing patented microbiome-based therapies, today announced that AOBiome has expanded its clinical-stage pipeline with the initiation of a randomized, double-blind, Phase 2 study to assess safety, tolerability, […]
Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota), is pleased to announce it has partnered with Chr. Hansen, a leading global bioscience company, to manufacture and supply pharmaceutical quality LGG®1 probiotic strain, Lactobacillus rhamnosus, initially […]
For the seventh year in a row, Dannon®, as a part of Danone North America, has demonstrated their commitment to science and education through the Dannon® Gut Microbiome, Yogurt and Probiotics Fellowship Grant Program. This […]
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a five year distribution agreement with Trigen Pharma International (Pvt) […]
Evolve BioSystems, Inc. and the icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh) today announced their collaboration, funded by the Bill & Melinda Gates Foundation, to study the use of Evivo® in infants to aid […]
Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg S.à.r.l.. The Munich-based chemical company announced the acquisition today. For WACKER, […]
NEW ORLEANS, April 11, 2018 /PRNewswire/ — MicroBiome Therapeutics, LLC (MBT), a leading company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness, today announced the launch of BiomeBliss™, a patented, […]
Second Genome, Inc., a leader in the development of novel medicines derived from the human microbiome, today announced the presentation of preclinical data and results from a Phase 1 study in healthy volunteers with its […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has agreed to sell 3,280,000 shares of its common stock to a large mutual […]
Osaka, Japan and Somerville, MA, April 5 2017 – Finch Therapeutics, a privately held microbiome engineering company, and Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), today announced a global collaboration agreement to jointly develop FIN-524. […]